Fenebrutinib for treating primary progressive multiple sclerosis [ID6543]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC
Fenebrutinib for treating relapsing multiple sclerosis [ID6577]Status:Awaiting developmentProgramme:Technology appraisal guidanceExpected publication date: TBC